MedPath

Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension

Not Applicable
Completed
Conditions
Pulmonary Hypertension
Interventions
Procedure: Right heart catheterization
Procedure: Near-infrared spectroscopy
Registration Number
NCT01463514
Lead Sponsor
University of Zurich
Brief Summary

To study the effect of acute pulmonary vasodilatation on cerebral tissue oxygenation (CTO) and cerebral blood flow (CBF) as indicator for cerebrovascular autoregulation in comparison to the effects of supplemental oxygen, decreased carbon dioxide by hyperventilation and exercise in patients with pulmonary hypertension (PH) undergoing clinically indicated right heart catheterisation (RHC).

Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. Non-invasive near infrared spectroscopy (NIRS) and a nasal canula will be additionally applied to measure CTO, CBF and endtidal CO2 (EtCO2). All parameters will be obtained at rest breathing room air, during an oxygen challenge, during standardized hyperventilation, under vasodilatation testing and during exercise in random, single-blinded sequences (except for exercise and hyperventilation). Pulmonary, systemic and cerebral oxygenation parameters and hemodynamics will be correlated with each other and functional class, quality of life, exercise and cognitive assessments at the time of the RHC and after three month.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Target OxygenNear-infrared spectroscopyRandomization sequences according to modified catheter protocol. 1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR
AIRRight heart catheterizationRandomization sequences according to modified catheter protocol. 1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen
AIRNear-infrared spectroscopyRandomization sequences according to modified catheter protocol. 1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen
NONear-infrared spectroscopyRandomization sequences according to modified catheter protocol. 1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen
OxygenNear-infrared spectroscopyRandomization sequences according to modified catheter protocol. 1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)
NORight heart catheterizationRandomization sequences according to modified catheter protocol. 1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen
OxygenRight heart catheterizationRandomization sequences according to modified catheter protocol. 1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)
Target OxygenRight heart catheterizationRandomization sequences according to modified catheter protocol. 1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR
Primary Outcome Measures
NameTimeMethod
Changes from baseline cerebral tissue oxygenation (in %) during right heart catheterization and after 3 monthFirst measurement (day 1 = day of examination) during right heart catherization and after 3 month (follow-up)

Acute effects (deviation from baseline measurements in % of oxygenated blood) of oxygen challenge, hyperventilation and vasodilator testing during right heart catheterization on cerebral tissue oxygenation in patients with pulmonay hypertension

Changes in cerebral blood flow (in % from baseline) during right heart catheterization and after 3 monthFirst measurement (day 1 = day of examination) during right heart catherization and after 3 month (follow-up)

Acute effects (deviation from baseline measurements in % from baseline) of oxygen challenge, hyperventilation and vasodilator testing during right heart catheterization on cerebral blood flow in patients with pulmonay hypertension

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University Hospital Zurich, Pneumology

🇨🇭

Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath